Ligand source activities (1 row/activity)



Get vendors


Ligands Receptor Assay information Chemical information
Sel. page Common
name		 GPCRdb ID #Vendors Reference
ligand		 Fold selectivity
(Potency)		 # tested GPCRs
(Potency)		 Species p-value
(-log)		 Type Activity
Relation		 Activity
Value		 Assay Type Assay Description Source Mol
weight		 Rot
Bonds		 H don H acc LogP Smiles DOI
155518674 169739 0 None - 1 Human 6.0 pEC50 = 6.0 Functional
Activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as activation of 3 uM strychnine-induced intracellular calcium level by FLIPR assayActivity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as activation of 3 uM strychnine-induced intracellular calcium level by FLIPR assay
ChEMBL 292 1 0 4 3.2 CC(=O)O[C@H]1C/C=C(\C)CCC2[C@@H](/C=C/1C)OC(=O)[C@H]2C nan
CHEMBL4446651 169739 0 None - 1 Human 6.0 pEC50 = 6.0 Functional
Activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as activation of 3 uM strychnine-induced intracellular calcium level by FLIPR assayActivity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as activation of 3 uM strychnine-induced intracellular calcium level by FLIPR assay
ChEMBL 292 1 0 4 3.2 CC(=O)O[C@H]1C/C=C(\C)CCC2[C@@H](/C=C/1C)OC(=O)[C@H]2C nan
155547566 173121 0 None - 1 Human 6.0 pEC50 = 6.0 Functional
Agonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as increase in intracellular calcium level by FLIPR assayAgonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as increase in intracellular calcium level by FLIPR assay
ChEMBL 292 1 0 4 3.2 CC(=O)O[C@H]1C/C=C(\C)CC[C@@H]2[C@@H](/C=C/1C)OC(=O)[C@H]2C nan
CHEMBL4535452 173121 0 None - 1 Human 6.0 pEC50 = 6.0 Functional
Agonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as increase in intracellular calcium level by FLIPR assayAgonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as increase in intracellular calcium level by FLIPR assay
ChEMBL 292 1 0 4 3.2 CC(=O)O[C@H]1C/C=C(\C)CC[C@@H]2[C@@H](/C=C/1C)OC(=O)[C@H]2C nan
68344426 175123 0 None 3 3 Human 4.7 pEC50 = 4.7 Functional
Competitive antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition strychnine-induced intracellular calcium level by measuring strychnine EC50 at 100 uM by FLIPR assay (Rvb = 0.39 +/- 0.08 uM)Competitive antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition strychnine-induced intracellular calcium level by measuring strychnine EC50 at 100 uM by FLIPR assay (Rvb = 0.39 +/- 0.08 uM)
ChEMBL 250 0 1 3 2.6 C/C1=C\C[C@H](O)/C(C)=C/[C@H]2OC(=O)[C@@H](C)C2CC1 nan
CHEMBL4582048 175123 0 None 3 3 Human 4.7 pEC50 = 4.7 Functional
Competitive antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition strychnine-induced intracellular calcium level by measuring strychnine EC50 at 100 uM by FLIPR assay (Rvb = 0.39 +/- 0.08 uM)Competitive antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition strychnine-induced intracellular calcium level by measuring strychnine EC50 at 100 uM by FLIPR assay (Rvb = 0.39 +/- 0.08 uM)
ChEMBL 250 0 1 3 2.6 C/C1=C\C[C@H](O)/C(C)=C/[C@H]2OC(=O)[C@@H](C)C2CC1 nan
68344426 175123 0 None 3 3 Human 5.6 pEC50 = 5.6 Functional
Competitive antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition strychnine-induced intracellular calcium level by measuring strychnine EC50 at 10 uM by FLIPR assay (Rvb = 0.39 +/- 0.08 uM)Competitive antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition strychnine-induced intracellular calcium level by measuring strychnine EC50 at 10 uM by FLIPR assay (Rvb = 0.39 +/- 0.08 uM)
ChEMBL 250 0 1 3 2.6 C/C1=C\C[C@H](O)/C(C)=C/[C@H]2OC(=O)[C@@H](C)C2CC1 nan
CHEMBL4582048 175123 0 None 3 3 Human 5.6 pEC50 = 5.6 Functional
Competitive antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition strychnine-induced intracellular calcium level by measuring strychnine EC50 at 10 uM by FLIPR assay (Rvb = 0.39 +/- 0.08 uM)Competitive antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition strychnine-induced intracellular calcium level by measuring strychnine EC50 at 10 uM by FLIPR assay (Rvb = 0.39 +/- 0.08 uM)
ChEMBL 250 0 1 3 2.6 C/C1=C\C[C@H](O)/C(C)=C/[C@H]2OC(=O)[C@@H](C)C2CC1 nan
5360696 1379 27 None -58 3 Human 4.5 pEC50 = 4.5 Functional
Agonist activity at human TAS2R46 stably expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4-AM dye based FLIPR assayAgonist activity at human TAS2R46 stably expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4-AM dye based FLIPR assay
ChEMBL 271 1 0 2 3.4 COc1ccc2c(c1)[C@@]13CCCC[C@@H]3[C@H](C2)N(CC1)C nan
6953 1379 27 None -58 3 Human 4.5 pEC50 = 4.5 Functional
Agonist activity at human TAS2R46 stably expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4-AM dye based FLIPR assayAgonist activity at human TAS2R46 stably expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4-AM dye based FLIPR assay
ChEMBL 271 1 0 2 3.4 COc1ccc2c(c1)[C@@]13CCCC[C@@H]3[C@H](C2)N(CC1)C nan
842 1379 27 None -58 3 Human 4.5 pEC50 = 4.5 Functional
Agonist activity at human TAS2R46 stably expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4-AM dye based FLIPR assayAgonist activity at human TAS2R46 stably expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4-AM dye based FLIPR assay
ChEMBL 271 1 0 2 3.4 COc1ccc2c(c1)[C@@]13CCCC[C@@H]3[C@H](C2)N(CC1)C nan
CHEMBL52440 1379 27 None -58 3 Human 4.5 pEC50 = 4.5 Functional
Agonist activity at human TAS2R46 stably expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4-AM dye based FLIPR assayAgonist activity at human TAS2R46 stably expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4-AM dye based FLIPR assay
ChEMBL 271 1 0 2 3.4 COc1ccc2c(c1)[C@@]13CCCC[C@@H]3[C@H](C2)N(CC1)C nan
DB00514 1379 27 None -58 3 Human 4.5 pEC50 = 4.5 Functional
Agonist activity at human TAS2R46 stably expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4-AM dye based FLIPR assayAgonist activity at human TAS2R46 stably expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4-AM dye based FLIPR assay
ChEMBL 271 1 0 2 3.4 COc1ccc2c(c1)[C@@]13CCCC[C@@H]3[C@H](C2)N(CC1)C nan
1499 2060 43 None -63 36 Human 8.3 pEC50 = 8.3 Functional
Agonist activity at human TAS2R46 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assayAgonist activity at human TAS2R46 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assay
ChEMBL 211 4 4 4 1.1 CC(NCC(c1ccc(c(c1)O)O)O)C nan
3779 2060 43 None -63 36 Human 8.3 pEC50 = 8.3 Functional
Agonist activity at human TAS2R46 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assayAgonist activity at human TAS2R46 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assay
ChEMBL 211 4 4 4 1.1 CC(NCC(c1ccc(c(c1)O)O)O)C nan
536 2060 43 None -63 36 Human 8.3 pEC50 = 8.3 Functional
Agonist activity at human TAS2R46 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assayAgonist activity at human TAS2R46 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assay
ChEMBL 211 4 4 4 1.1 CC(NCC(c1ccc(c(c1)O)O)O)C nan
CHEMBL434 2060 43 None -63 36 Human 8.3 pEC50 = 8.3 Functional
Agonist activity at human TAS2R46 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assayAgonist activity at human TAS2R46 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assay
ChEMBL 211 4 4 4 1.1 CC(NCC(c1ccc(c(c1)O)O)O)C nan
DB01064 2060 43 None -63 36 Human 8.3 pEC50 = 8.3 Functional
Agonist activity at human TAS2R46 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assayAgonist activity at human TAS2R46 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assay
ChEMBL 211 4 4 4 1.1 CC(NCC(c1ccc(c(c1)O)O)O)C nan
68344426 175123 0 None 3 3 Human 5.3 pEC50 = 5.3 Functional
Competitive antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition strychnine-induced intracellular calcium level by measuring strychnine EC50 at 30 uM by FLIPR assay (Rvb = 0.39 +/- 0.08 uM)Competitive antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition strychnine-induced intracellular calcium level by measuring strychnine EC50 at 30 uM by FLIPR assay (Rvb = 0.39 +/- 0.08 uM)
ChEMBL 250 0 1 3 2.6 C/C1=C\C[C@H](O)/C(C)=C/[C@H]2OC(=O)[C@@H](C)C2CC1 nan
CHEMBL4582048 175123 0 None 3 3 Human 5.3 pEC50 = 5.3 Functional
Competitive antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition strychnine-induced intracellular calcium level by measuring strychnine EC50 at 30 uM by FLIPR assay (Rvb = 0.39 +/- 0.08 uM)Competitive antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition strychnine-induced intracellular calcium level by measuring strychnine EC50 at 30 uM by FLIPR assay (Rvb = 0.39 +/- 0.08 uM)
ChEMBL 250 0 1 3 2.6 C/C1=C\C[C@H](O)/C(C)=C/[C@H]2OC(=O)[C@@H](C)C2CC1 nan
2360 3637 41 None 19 2 Human 6.2 pEC50 = 6.2 Functional
Agonist activity at human TAS2R46 stably expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4-AM dye based FLIPR assayAgonist activity at human TAS2R46 stably expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4-AM dye based FLIPR assay
ChEMBL 334 0 0 3 2.1 O=C1C[C@@H]2OCC=C3[C@H]4[C@@H]2[C@@H]2N1c1ccccc1[C@]12CCN([C@H]1C4)C3 nan
2484 3637 41 None 19 2 Human 6.2 pEC50 = 6.2 Functional
Agonist activity at human TAS2R46 stably expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4-AM dye based FLIPR assayAgonist activity at human TAS2R46 stably expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4-AM dye based FLIPR assay
ChEMBL 334 0 0 3 2.1 O=C1C[C@@H]2OCC=C3[C@H]4[C@@H]2[C@@H]2N1c1ccccc1[C@]12CCN([C@H]1C4)C3 nan
347 3637 41 None 19 2 Human 6.2 pEC50 = 6.2 Functional
Agonist activity at human TAS2R46 stably expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4-AM dye based FLIPR assayAgonist activity at human TAS2R46 stably expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4-AM dye based FLIPR assay
ChEMBL 334 0 0 3 2.1 O=C1C[C@@H]2OCC=C3[C@H]4[C@@H]2[C@@H]2N1c1ccccc1[C@]12CCN([C@H]1C4)C3 nan
441071 3637 41 None 19 2 Human 6.2 pEC50 = 6.2 Functional
Agonist activity at human TAS2R46 stably expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4-AM dye based FLIPR assayAgonist activity at human TAS2R46 stably expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4-AM dye based FLIPR assay
ChEMBL 334 0 0 3 2.1 O=C1C[C@@H]2OCC=C3[C@H]4[C@@H]2[C@@H]2N1c1ccccc1[C@]12CCN([C@H]1C4)C3 nan
CHEMBL227934 3637 41 None 19 2 Human 6.2 pEC50 = 6.2 Functional
Agonist activity at human TAS2R46 stably expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4-AM dye based FLIPR assayAgonist activity at human TAS2R46 stably expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4-AM dye based FLIPR assay
ChEMBL 334 0 0 3 2.1 O=C1C[C@@H]2OCC=C3[C@H]4[C@@H]2[C@@H]2N1c1ccccc1[C@]12CCN([C@H]1C4)C3 nan
DB15954 3637 41 None 19 2 Human 6.2 pEC50 = 6.2 Functional
Agonist activity at human TAS2R46 stably expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4-AM dye based FLIPR assayAgonist activity at human TAS2R46 stably expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4-AM dye based FLIPR assay
ChEMBL 334 0 0 3 2.1 O=C1C[C@@H]2OCC=C3[C@H]4[C@@H]2[C@@H]2N1c1ccccc1[C@]12CCN([C@H]1C4)C3 nan
155559967 174329 0 None - 1 Human 5.1 pEC50 = 5.1 Functional
Activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as activation of 3 uM strychnine-induced intracellular calcium level by FLIPR assayActivity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as activation of 3 uM strychnine-induced intracellular calcium level by FLIPR assay
ChEMBL 234 0 0 2 3.6 C/C1=C\[C@H]2OC(=O)[C@@H](C)C2CC/C(C)=C/CC1 nan
CHEMBL4564347 174329 0 None - 1 Human 5.1 pEC50 = 5.1 Functional
Activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as activation of 3 uM strychnine-induced intracellular calcium level by FLIPR assayActivity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as activation of 3 uM strychnine-induced intracellular calcium level by FLIPR assay
ChEMBL 234 0 0 2 3.6 C/C1=C\[C@H]2OC(=O)[C@@H](C)C2CC/C(C)=C/CC1 nan
6917068 187611 1 None - 1 Human 5.1 pEC50 = 5.1 Functional
Agonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as increase in intracellular calcium level by FLIPR assayAgonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as increase in intracellular calcium level by FLIPR assay
ChEMBL 234 0 0 2 3.6 C/C1=C\[C@H]2OC(=O)[C@@H](C)[C@@H]2CC/C(C)=C/CC1 nan
CHEMBL499003 187611 1 None - 1 Human 5.1 pEC50 = 5.1 Functional
Agonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as increase in intracellular calcium level by FLIPR assayAgonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as increase in intracellular calcium level by FLIPR assay
ChEMBL 234 0 0 2 3.6 C/C1=C\[C@H]2OC(=O)[C@@H](C)[C@@H]2CC/C(C)=C/CC1 nan
5316108 168963 1 None - 1 Human 5.1 pEC50 = 5.1 Functional
Activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as activation of 3 uM strychnine-induced intracellular calcium level by FLIPR assayActivity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as activation of 3 uM strychnine-induced intracellular calcium level by FLIPR assay
ChEMBL 232 0 0 2 3.6 C=C1C(=O)O[C@@H]2/C=C(\C)CC/C=C(\C)CCC12 nan
CHEMBL4435198 168963 1 None - 1 Human 5.1 pEC50 = 5.1 Functional
Activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as activation of 3 uM strychnine-induced intracellular calcium level by FLIPR assayActivity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as activation of 3 uM strychnine-induced intracellular calcium level by FLIPR assay
ChEMBL 232 0 0 2 3.6 C=C1C(=O)O[C@@H]2/C=C(\C)CC/C=C(\C)CCC12 nan
5281437 204465 54 None - 1 Human 5.1 pEC50 = 5.1 Functional
Agonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as increase in intracellular calcium level by FLIPR assayAgonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as increase in intracellular calcium level by FLIPR assay
ChEMBL 232 0 0 2 3.6 C=C1C(=O)O[C@@H]2/C=C(\C)CC/C=C(\C)CC[C@@H]12 nan
CHEMBL86416 204465 54 None - 1 Human 5.1 pEC50 = 5.1 Functional
Agonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as increase in intracellular calcium level by FLIPR assayAgonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as increase in intracellular calcium level by FLIPR assay
ChEMBL 232 0 0 2 3.6 C=C1C(=O)O[C@@H]2/C=C(\C)CC/C=C(\C)CC[C@@H]12 nan
68344426 175123 0 None 3 3 Human 4.9 pIC50 = 4.9 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 100 uM absinthin-induced intracellular calcium level 100 uM by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 100 uM absinthin-induced intracellular calcium level 100 uM by FLIPR assay
ChEMBL 250 0 1 3 2.6 C/C1=C\C[C@H](O)/C(C)=C/[C@H]2OC(=O)[C@@H](C)C2CC1 nan
CHEMBL4582048 175123 0 None 3 3 Human 4.9 pIC50 = 4.9 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 100 uM absinthin-induced intracellular calcium level 100 uM by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 100 uM absinthin-induced intracellular calcium level 100 uM by FLIPR assay
ChEMBL 250 0 1 3 2.6 C/C1=C\C[C@H](O)/C(C)=C/[C@H]2OC(=O)[C@@H](C)C2CC1 nan
23259348 169346 0 None 1 3 Human 4.9 pIC50 = 4.9 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of absinthin-induced increase in intracellular calcium level by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of absinthin-induced increase in intracellular calcium level by FLIPR assay
ChEMBL 250 0 1 3 2.6 C/C1=C\C[C@H](O)/C(C)=C/[C@H]2OC(=O)[C@@H](C)[C@@H]2CC1 nan
CHEMBL4440983 169346 0 None 1 3 Human 4.9 pIC50 = 4.9 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of absinthin-induced increase in intracellular calcium level by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of absinthin-induced increase in intracellular calcium level by FLIPR assay
ChEMBL 250 0 1 3 2.6 C/C1=C\C[C@H](O)/C(C)=C/[C@H]2OC(=O)[C@@H](C)[C@@H]2CC1 nan
68344426 175123 0 None 3 3 Human 4.8 pIC50 = 4.8 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 3 uM strychnine-induced intracellular calcium level 100 uM by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 3 uM strychnine-induced intracellular calcium level 100 uM by FLIPR assay
ChEMBL 250 0 1 3 2.6 C/C1=C\C[C@H](O)/C(C)=C/[C@H]2OC(=O)[C@@H](C)C2CC1 nan
CHEMBL4582048 175123 0 None 3 3 Human 4.8 pIC50 = 4.8 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 3 uM strychnine-induced intracellular calcium level 100 uM by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 3 uM strychnine-induced intracellular calcium level 100 uM by FLIPR assay
ChEMBL 250 0 1 3 2.6 C/C1=C\C[C@H](O)/C(C)=C/[C@H]2OC(=O)[C@@H](C)C2CC1 nan
68344426 175123 0 None 3 3 Human 4.8 pIC50 = 4.8 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 3 uM strychnine-induced intracellular calcium level by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 3 uM strychnine-induced intracellular calcium level by FLIPR assay
ChEMBL 250 0 1 3 2.6 C/C1=C\C[C@H](O)/C(C)=C/[C@H]2OC(=O)[C@@H](C)C2CC1 nan
CHEMBL4582048 175123 0 None 3 3 Human 4.8 pIC50 = 4.8 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 3 uM strychnine-induced intracellular calcium level by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 3 uM strychnine-induced intracellular calcium level by FLIPR assay
ChEMBL 250 0 1 3 2.6 C/C1=C\C[C@H](O)/C(C)=C/[C@H]2OC(=O)[C@@H](C)C2CC1 nan
23259348 169346 0 None 1 3 Human 4.8 pIC50 = 4.8 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of strychnine-induced increase in intracellular calcium level by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of strychnine-induced increase in intracellular calcium level by FLIPR assay
ChEMBL 250 0 1 3 2.6 C/C1=C\C[C@H](O)/C(C)=C/[C@H]2OC(=O)[C@@H](C)[C@@H]2CC1 nan
CHEMBL4440983 169346 0 None 1 3 Human 4.8 pIC50 = 4.8 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of strychnine-induced increase in intracellular calcium level by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of strychnine-induced increase in intracellular calcium level by FLIPR assay
ChEMBL 250 0 1 3 2.6 C/C1=C\C[C@H](O)/C(C)=C/[C@H]2OC(=O)[C@@H](C)[C@@H]2CC1 nan
155550031 173337 0 None - 1 Human 4.6 pIC50 = 4.6 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 300 uM picrotoxinin-induced intracellular calcium level 100 uM by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 300 uM picrotoxinin-induced intracellular calcium level 100 uM by FLIPR assay
ChEMBL 252 0 1 3 2.7 C/C1=C\C[C@H](O)[C@@H](C)C[C@H]2OC(=O)[C@@H](C)C2CC1 nan
CHEMBL4540311 173337 0 None - 1 Human 4.6 pIC50 = 4.6 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 300 uM picrotoxinin-induced intracellular calcium level 100 uM by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 300 uM picrotoxinin-induced intracellular calcium level 100 uM by FLIPR assay
ChEMBL 252 0 1 3 2.7 C/C1=C\C[C@H](O)[C@@H](C)C[C@H]2OC(=O)[C@@H](C)C2CC1 nan
68344591 169845 0 None - 1 Human 4.6 pIC50 = 4.6 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of picrotoxinin-induced intracellular calcium level by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of picrotoxinin-induced intracellular calcium level by FLIPR assay
ChEMBL 252 0 1 3 2.7 C/C1=C\C[C@H](O)[C@@H](C)C[C@H]2OC(=O)[C@@H](C)[C@@H]2CC1 nan
CHEMBL4448202 169845 0 None - 1 Human 4.6 pIC50 = 4.6 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of picrotoxinin-induced intracellular calcium level by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of picrotoxinin-induced intracellular calcium level by FLIPR assay
ChEMBL 252 0 1 3 2.7 C/C1=C\C[C@H](O)[C@@H](C)C[C@H]2OC(=O)[C@@H](C)[C@@H]2CC1 nan
155550031 173337 0 None - 1 Human 4.4 pIC50 = 4.4 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 30 uM andrographolide-induced intracellular calcium level 100 uM by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 30 uM andrographolide-induced intracellular calcium level 100 uM by FLIPR assay
ChEMBL 252 0 1 3 2.7 C/C1=C\C[C@H](O)[C@@H](C)C[C@H]2OC(=O)[C@@H](C)C2CC1 nan
CHEMBL4540311 173337 0 None - 1 Human 4.4 pIC50 = 4.4 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 30 uM andrographolide-induced intracellular calcium level 100 uM by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 30 uM andrographolide-induced intracellular calcium level 100 uM by FLIPR assay
ChEMBL 252 0 1 3 2.7 C/C1=C\C[C@H](O)[C@@H](C)C[C@H]2OC(=O)[C@@H](C)C2CC1 nan
68344591 169845 0 None - 1 Human 4.4 pIC50 = 4.4 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of andrographolide-induced increase in intracellular calcium level by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of andrographolide-induced increase in intracellular calcium level by FLIPR assay
ChEMBL 252 0 1 3 2.7 C/C1=C\C[C@H](O)[C@@H](C)C[C@H]2OC(=O)[C@@H](C)[C@@H]2CC1 nan
CHEMBL4448202 169845 0 None - 1 Human 4.4 pIC50 = 4.4 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of andrographolide-induced increase in intracellular calcium level by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of andrographolide-induced increase in intracellular calcium level by FLIPR assay
ChEMBL 252 0 1 3 2.7 C/C1=C\C[C@H](O)[C@@H](C)C[C@H]2OC(=O)[C@@H](C)[C@@H]2CC1 nan
68344426 175123 0 None 3 3 Human 5.3 pIC50 = 5.3 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 300 uM picrotoxinin-induced intracellular calcium level 100 uM by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 300 uM picrotoxinin-induced intracellular calcium level 100 uM by FLIPR assay
ChEMBL 250 0 1 3 2.6 C/C1=C\C[C@H](O)/C(C)=C/[C@H]2OC(=O)[C@@H](C)C2CC1 nan
CHEMBL4582048 175123 0 None 3 3 Human 5.3 pIC50 = 5.3 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 300 uM picrotoxinin-induced intracellular calcium level 100 uM by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 300 uM picrotoxinin-induced intracellular calcium level 100 uM by FLIPR assay
ChEMBL 250 0 1 3 2.6 C/C1=C\C[C@H](O)/C(C)=C/[C@H]2OC(=O)[C@@H](C)C2CC1 nan
23259348 169346 0 None 1 3 Human 5.3 pIC50 = 5.3 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of picrotoxinin-induced intracellular calcium level by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of picrotoxinin-induced intracellular calcium level by FLIPR assay
ChEMBL 250 0 1 3 2.6 C/C1=C\C[C@H](O)/C(C)=C/[C@H]2OC(=O)[C@@H](C)[C@@H]2CC1 nan
CHEMBL4440983 169346 0 None 1 3 Human 5.3 pIC50 = 5.3 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of picrotoxinin-induced intracellular calcium level by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of picrotoxinin-induced intracellular calcium level by FLIPR assay
ChEMBL 250 0 1 3 2.6 C/C1=C\C[C@H](O)/C(C)=C/[C@H]2OC(=O)[C@@H](C)[C@@H]2CC1 nan
68344426 175123 0 None 3 3 Human 5.3 pIC50 = 5.3 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 30 uM andrographolide-induced intracellular calcium level 100 uM by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 30 uM andrographolide-induced intracellular calcium level 100 uM by FLIPR assay
ChEMBL 250 0 1 3 2.6 C/C1=C\C[C@H](O)/C(C)=C/[C@H]2OC(=O)[C@@H](C)C2CC1 nan
CHEMBL4582048 175123 0 None 3 3 Human 5.3 pIC50 = 5.3 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 30 uM andrographolide-induced intracellular calcium level 100 uM by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 30 uM andrographolide-induced intracellular calcium level 100 uM by FLIPR assay
ChEMBL 250 0 1 3 2.6 C/C1=C\C[C@H](O)/C(C)=C/[C@H]2OC(=O)[C@@H](C)C2CC1 nan
23259348 169346 0 None 1 3 Human 5.3 pIC50 = 5.3 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of andrographolide-induced increase in intracellular calcium level by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of andrographolide-induced increase in intracellular calcium level by FLIPR assay
ChEMBL 250 0 1 3 2.6 C/C1=C\C[C@H](O)/C(C)=C/[C@H]2OC(=O)[C@@H](C)[C@@H]2CC1 nan
CHEMBL4440983 169346 0 None 1 3 Human 5.3 pIC50 = 5.3 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of andrographolide-induced increase in intracellular calcium level by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of andrographolide-induced increase in intracellular calcium level by FLIPR assay
ChEMBL 250 0 1 3 2.6 C/C1=C\C[C@H](O)/C(C)=C/[C@H]2OC(=O)[C@@H](C)[C@@H]2CC1 nan
155550031 173337 0 None - 1 Human 4.3 pIC50 = 4.3 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 300 uM denatonium benzoate-induced intracellular calcium level 100 uM by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 300 uM denatonium benzoate-induced intracellular calcium level 100 uM by FLIPR assay
ChEMBL 252 0 1 3 2.7 C/C1=C\C[C@H](O)[C@@H](C)C[C@H]2OC(=O)[C@@H](C)C2CC1 nan
CHEMBL4540311 173337 0 None - 1 Human 4.3 pIC50 = 4.3 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 300 uM denatonium benzoate-induced intracellular calcium level 100 uM by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 300 uM denatonium benzoate-induced intracellular calcium level 100 uM by FLIPR assay
ChEMBL 252 0 1 3 2.7 C/C1=C\C[C@H](O)[C@@H](C)C[C@H]2OC(=O)[C@@H](C)C2CC1 nan
68344591 169845 0 None - 1 Human 4.3 pIC50 = 4.3 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of denatonium benzoate-induced increase in intracellular calcium level by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of denatonium benzoate-induced increase in intracellular calcium level by FLIPR assay
ChEMBL 252 0 1 3 2.7 C/C1=C\C[C@H](O)[C@@H](C)C[C@H]2OC(=O)[C@@H](C)[C@@H]2CC1 nan
CHEMBL4448202 169845 0 None - 1 Human 4.3 pIC50 = 4.3 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of denatonium benzoate-induced increase in intracellular calcium level by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of denatonium benzoate-induced increase in intracellular calcium level by FLIPR assay
ChEMBL 252 0 1 3 2.7 C/C1=C\C[C@H](O)[C@@H](C)C[C@H]2OC(=O)[C@@H](C)[C@@H]2CC1 nan
155550031 173337 0 None - 1 Human 4.2 pIC50 = 4.2 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 100 uM absinthin-induced intracellular calcium level 100 uM by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 100 uM absinthin-induced intracellular calcium level 100 uM by FLIPR assay
ChEMBL 252 0 1 3 2.7 C/C1=C\C[C@H](O)[C@@H](C)C[C@H]2OC(=O)[C@@H](C)C2CC1 nan
CHEMBL4540311 173337 0 None - 1 Human 4.2 pIC50 = 4.2 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 100 uM absinthin-induced intracellular calcium level 100 uM by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 100 uM absinthin-induced intracellular calcium level 100 uM by FLIPR assay
ChEMBL 252 0 1 3 2.7 C/C1=C\C[C@H](O)[C@@H](C)C[C@H]2OC(=O)[C@@H](C)C2CC1 nan
68344591 169845 0 None - 1 Human 4.2 pIC50 = 4.2 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of absinthin-induced increase in intracellular calcium level by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of absinthin-induced increase in intracellular calcium level by FLIPR assay
ChEMBL 252 0 1 3 2.7 C/C1=C\C[C@H](O)[C@@H](C)C[C@H]2OC(=O)[C@@H](C)[C@@H]2CC1 nan
CHEMBL4448202 169845 0 None - 1 Human 4.2 pIC50 = 4.2 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of absinthin-induced increase in intracellular calcium level by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of absinthin-induced increase in intracellular calcium level by FLIPR assay
ChEMBL 252 0 1 3 2.7 C/C1=C\C[C@H](O)[C@@H](C)C[C@H]2OC(=O)[C@@H](C)[C@@H]2CC1 nan
68344426 175123 0 None 3 3 Human 5.2 pIC50 = 5.2 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 300 uM denatonium benzoate-induced intracellular calcium level 100 uM by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 300 uM denatonium benzoate-induced intracellular calcium level 100 uM by FLIPR assay
ChEMBL 250 0 1 3 2.6 C/C1=C\C[C@H](O)/C(C)=C/[C@H]2OC(=O)[C@@H](C)C2CC1 nan
CHEMBL4582048 175123 0 None 3 3 Human 5.2 pIC50 = 5.2 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 300 uM denatonium benzoate-induced intracellular calcium level 100 uM by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 300 uM denatonium benzoate-induced intracellular calcium level 100 uM by FLIPR assay
ChEMBL 250 0 1 3 2.6 C/C1=C\C[C@H](O)/C(C)=C/[C@H]2OC(=O)[C@@H](C)C2CC1 nan
23259348 169346 0 None 1 3 Human 5.2 pIC50 = 5.2 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of denatonium benzoate-induced increase in intracellular calcium level by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of denatonium benzoate-induced increase in intracellular calcium level by FLIPR assay
ChEMBL 250 0 1 3 2.6 C/C1=C\C[C@H](O)/C(C)=C/[C@H]2OC(=O)[C@@H](C)[C@@H]2CC1 nan
CHEMBL4440983 169346 0 None 1 3 Human 5.2 pIC50 = 5.2 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of denatonium benzoate-induced increase in intracellular calcium level by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of denatonium benzoate-induced increase in intracellular calcium level by FLIPR assay
ChEMBL 250 0 1 3 2.6 C/C1=C\C[C@H](O)/C(C)=C/[C@H]2OC(=O)[C@@H](C)[C@@H]2CC1 nan
155550031 173337 0 None - 1 Human 4.1 pIC50 = 4.1 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 3 uM strychnine-induced intracellular calcium level 100 uM by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 3 uM strychnine-induced intracellular calcium level 100 uM by FLIPR assay
ChEMBL 252 0 1 3 2.7 C/C1=C\C[C@H](O)[C@@H](C)C[C@H]2OC(=O)[C@@H](C)C2CC1 nan
CHEMBL4540311 173337 0 None - 1 Human 4.1 pIC50 = 4.1 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 3 uM strychnine-induced intracellular calcium level 100 uM by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 3 uM strychnine-induced intracellular calcium level 100 uM by FLIPR assay
ChEMBL 252 0 1 3 2.7 C/C1=C\C[C@H](O)[C@@H](C)C[C@H]2OC(=O)[C@@H](C)C2CC1 nan
68344591 169845 0 None - 1 Human 4.1 pIC50 = 4.1 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of strychnine-induced increase in intracellular calcium level by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of strychnine-induced increase in intracellular calcium level by FLIPR assay
ChEMBL 252 0 1 3 2.7 C/C1=C\C[C@H](O)[C@@H](C)C[C@H]2OC(=O)[C@@H](C)[C@@H]2CC1 nan
CHEMBL4448202 169845 0 None - 1 Human 4.1 pIC50 = 4.1 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of strychnine-induced increase in intracellular calcium level by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of strychnine-induced increase in intracellular calcium level by FLIPR assay
ChEMBL 252 0 1 3 2.7 C/C1=C\C[C@H](O)[C@@H](C)C[C@H]2OC(=O)[C@@H](C)[C@@H]2CC1 nan
155523720 170348 0 None - 1 Human 4.0 pIC50 = 4.0 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 3 uM strychnine-induced intracellular calcium level by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 3 uM strychnine-induced intracellular calcium level by FLIPR assay
ChEMBL 248 0 0 3 2.8 C/C1=C\CC(=O)/C(C)=C/[C@H]2OC(=O)[C@@H](C)C2CC1 nan
CHEMBL4454982 170348 0 None - 1 Human 4.0 pIC50 = 4.0 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 3 uM strychnine-induced intracellular calcium level by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of 3 uM strychnine-induced intracellular calcium level by FLIPR assay
ChEMBL 248 0 0 3 2.8 C/C1=C\CC(=O)/C(C)=C/[C@H]2OC(=O)[C@@H](C)C2CC1 nan
155552983 173516 0 None - 1 Human 4.0 pIC50 = 4.0 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of strychnine-induced increase in intracellular calcium level by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of strychnine-induced increase in intracellular calcium level by FLIPR assay
ChEMBL 248 0 0 3 2.8 C/C1=C\CC(=O)/C(C)=C/[C@H]2OC(=O)[C@@H](C)[C@@H]2CC1 nan
CHEMBL4544657 173516 0 None - 1 Human 4.0 pIC50 = 4.0 Functional
Antagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of strychnine-induced increase in intracellular calcium level by FLIPR assayAntagonist activity at recombinant human N-terminal rat ST3 receptor-fused TAS2R46 expressed in HEK293T cells co-expressing Galpha16gust44 assessed as inhibition of strychnine-induced increase in intracellular calcium level by FLIPR assay
ChEMBL 248 0 0 3 2.8 C/C1=C\CC(=O)/C(C)=C/[C@H]2OC(=O)[C@@H](C)[C@@H]2CC1 nan
5360696 1379 27 None -58 3 Human 8.4 pEC50 = 8.4 Functional
Agonist activity at human TAS2R46 stably expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4-AM dye based FLIPR assayAgonist activity at human TAS2R46 stably expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4-AM dye based FLIPR assay
Drug Central 271 1 0 2 3.4 COc1ccc2c(c1)[C@@]13CCCC[C@@H]3[C@H](C2)N(CC1)C None
6953 1379 27 None -58 3 Human 8.4 pEC50 = 8.4 Functional
Agonist activity at human TAS2R46 stably expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4-AM dye based FLIPR assayAgonist activity at human TAS2R46 stably expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4-AM dye based FLIPR assay
Drug Central 271 1 0 2 3.4 COc1ccc2c(c1)[C@@]13CCCC[C@@H]3[C@H](C2)N(CC1)C None
842 1379 27 None -58 3 Human 8.4 pEC50 = 8.4 Functional
Agonist activity at human TAS2R46 stably expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4-AM dye based FLIPR assayAgonist activity at human TAS2R46 stably expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4-AM dye based FLIPR assay
Drug Central 271 1 0 2 3.4 COc1ccc2c(c1)[C@@]13CCCC[C@@H]3[C@H](C2)N(CC1)C None
CHEMBL52440 1379 27 None -58 3 Human 8.4 pEC50 = 8.4 Functional
Agonist activity at human TAS2R46 stably expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4-AM dye based FLIPR assayAgonist activity at human TAS2R46 stably expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4-AM dye based FLIPR assay
Drug Central 271 1 0 2 3.4 COc1ccc2c(c1)[C@@]13CCCC[C@@H]3[C@H](C2)N(CC1)C None
DB00514 1379 27 None -58 3 Human 8.4 pEC50 = 8.4 Functional
Agonist activity at human TAS2R46 stably expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4-AM dye based FLIPR assayAgonist activity at human TAS2R46 stably expressed in HEK293T/Galpha16-gustducin 44 cells assessed as effect on calcium flux by measuring deltaF/F0 ratio by Fluo-4-AM dye based FLIPR assay
Drug Central 271 1 0 2 3.4 COc1ccc2c(c1)[C@@]13CCCC[C@@H]3[C@H](C2)N(CC1)C None
2360 3637 41 None 19 2 Human 8.2 pEC50 = 8.2 Functional
calcium imaging in ransfected human embryonic kidney (HEK)-293Tcalcium imaging in ransfected human embryonic kidney (HEK)-293T
Drug Central 334 0 0 3 2.1 O=C1C[C@@H]2OCC=C3[C@H]4[C@@H]2[C@@H]2N1c1ccccc1[C@]12CCN([C@H]1C4)C3 None
2484 3637 41 None 19 2 Human 8.2 pEC50 = 8.2 Functional
calcium imaging in ransfected human embryonic kidney (HEK)-293Tcalcium imaging in ransfected human embryonic kidney (HEK)-293T
Drug Central 334 0 0 3 2.1 O=C1C[C@@H]2OCC=C3[C@H]4[C@@H]2[C@@H]2N1c1ccccc1[C@]12CCN([C@H]1C4)C3 None
347 3637 41 None 19 2 Human 8.2 pEC50 = 8.2 Functional
calcium imaging in ransfected human embryonic kidney (HEK)-293Tcalcium imaging in ransfected human embryonic kidney (HEK)-293T
Drug Central 334 0 0 3 2.1 O=C1C[C@@H]2OCC=C3[C@H]4[C@@H]2[C@@H]2N1c1ccccc1[C@]12CCN([C@H]1C4)C3 None
441071 3637 41 None 19 2 Human 8.2 pEC50 = 8.2 Functional
calcium imaging in ransfected human embryonic kidney (HEK)-293Tcalcium imaging in ransfected human embryonic kidney (HEK)-293T
Drug Central 334 0 0 3 2.1 O=C1C[C@@H]2OCC=C3[C@H]4[C@@H]2[C@@H]2N1c1ccccc1[C@]12CCN([C@H]1C4)C3 None
CHEMBL227934 3637 41 None 19 2 Human 8.2 pEC50 = 8.2 Functional
calcium imaging in ransfected human embryonic kidney (HEK)-293Tcalcium imaging in ransfected human embryonic kidney (HEK)-293T
Drug Central 334 0 0 3 2.1 O=C1C[C@@H]2OCC=C3[C@H]4[C@@H]2[C@@H]2N1c1ccccc1[C@]12CCN([C@H]1C4)C3 None
DB15954 3637 41 None 19 2 Human 8.2 pEC50 = 8.2 Functional
calcium imaging in ransfected human embryonic kidney (HEK)-293Tcalcium imaging in ransfected human embryonic kidney (HEK)-293T
Drug Central 334 0 0 3 2.1 O=C1C[C@@H]2OCC=C3[C@H]4[C@@H]2[C@@H]2N1c1ccccc1[C@]12CCN([C@H]1C4)C3 None
1499 2060 43 None -63 36 Human 8.1 pEC50 = 8.1 Functional
Agonist activity at human TAS2R46 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assayAgonist activity at human TAS2R46 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assay
Drug Central 211 4 4 4 1.1 CC(NCC(c1ccc(c(c1)O)O)O)C None
3779 2060 43 None -63 36 Human 8.1 pEC50 = 8.1 Functional
Agonist activity at human TAS2R46 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assayAgonist activity at human TAS2R46 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assay
Drug Central 211 4 4 4 1.1 CC(NCC(c1ccc(c(c1)O)O)O)C None
536 2060 43 None -63 36 Human 8.1 pEC50 = 8.1 Functional
Agonist activity at human TAS2R46 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assayAgonist activity at human TAS2R46 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assay
Drug Central 211 4 4 4 1.1 CC(NCC(c1ccc(c(c1)O)O)O)C None
CHEMBL434 2060 43 None -63 36 Human 8.1 pEC50 = 8.1 Functional
Agonist activity at human TAS2R46 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assayAgonist activity at human TAS2R46 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assay
Drug Central 211 4 4 4 1.1 CC(NCC(c1ccc(c(c1)O)O)O)C None
DB01064 2060 43 None -63 36 Human 8.1 pEC50 = 8.1 Functional
Agonist activity at human TAS2R46 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assayAgonist activity at human TAS2R46 expressed in HEK293T cells co-expressing Galpha15 assessed as increase in intracellular calcium level by Calcium-3 dye based fluorescence assay
Drug Central 211 4 4 4 1.1 CC(NCC(c1ccc(c(c1)O)O)O)C None
2367 950 83 None -1778 5 Human 2.8 pEC50 = 2.8 Functional
UnclassifiedUnclassified
Guide to Pharmacology 399 5 1 6 2.9 COc1c(OC)cc2c(c1OC)c1ccc(c(=O)cc1[C@H](CC2)NC(=O)C)OC 20022913
6167 950 83 None -1778 5 Human 2.8 pEC50 = 2.8 Functional
UnclassifiedUnclassified
Guide to Pharmacology 399 5 1 6 2.9 COc1c(OC)cc2c(c1OC)c1ccc(c(=O)cc1[C@H](CC2)NC(=O)C)OC 20022913
726 950 83 None -1778 5 Human 2.8 pEC50 = 2.8 Functional
UnclassifiedUnclassified
Guide to Pharmacology 399 5 1 6 2.9 COc1c(OC)cc2c(c1OC)c1ccc(c(=O)cc1[C@H](CC2)NC(=O)C)OC 20022913
CHEMBL107 950 83 None -1778 5 Human 2.8 pEC50 = 2.8 Functional
UnclassifiedUnclassified
Guide to Pharmacology 399 5 1 6 2.9 COc1c(OC)cc2c(c1OC)c1ccc(c(=O)cc1[C@H](CC2)NC(=O)C)OC 20022913
DB01394 950 83 None -1778 5 Human 2.8 pEC50 = 2.8 Functional
UnclassifiedUnclassified
Guide to Pharmacology 399 5 1 6 2.9 COc1c(OC)cc2c(c1OC)c1ccc(c(=O)cc1[C@H](CC2)NC(=O)C)OC 20022913
12433 1338 9 None -891 4 Human 3.6 pEC50 = 3.6 Functional
UnclassifiedUnclassified
Guide to Pharmacology 325 7 1 1 4.3 CC[N+](CC)(CC1=CC=CC=C1)CC(=O)NC2=C(C=CC=C2C)C 20022913
15488 1338 9 None -891 4 Human 3.6 pEC50 = 3.6 Functional
UnclassifiedUnclassified
Guide to Pharmacology 325 7 1 1 4.3 CC[N+](CC)(CC1=CC=CC=C1)CC(=O)NC2=C(C=CC=C2C)C 20022913
CHEMBL1738972 1338 9 None -891 4 Human 3.6 pEC50 = 3.6 Functional
UnclassifiedUnclassified
Guide to Pharmacology 325 7 1 1 4.3 CC[N+](CC)(CC1=CC=CC=C1)CC(=O)NC2=C(C=CC=C2C)C 20022913
2291 3073 0 None -3 2 Human 4.2 pEC50 = 4.2 Functional
UnclassifiedUnclassified
Guide to Pharmacology 292 1 1 6 -0.1 CC(=C)[C@@H]1[C@H]2OC(=O)[C@@H]1[C@]1([C@]3([C@@H]2OC(=O)[C@]23[C@@H](C1)O2)C)O 17595105
442292 3073 0 None -3 2 Human 4.2 pEC50 = 4.2 Functional
UnclassifiedUnclassified
Guide to Pharmacology 292 1 1 6 -0.1 CC(=C)[C@@H]1[C@H]2OC(=O)[C@@H]1[C@]1([C@]3([C@@H]2OC(=O)[C@]23[C@@H](C1)O2)C)O 17595105
CHEMBL47244 3073 0 None -3 2 Human 4.2 pEC50 = 4.2 Functional
UnclassifiedUnclassified
Guide to Pharmacology 292 1 1 6 -0.1 CC(=C)[C@@H]1[C@H]2OC(=O)[C@@H]1[C@]1([C@]3([C@@H]2OC(=O)[C@]23[C@@H](C1)O2)C)O 17595105
115149 387 0 None -165 3 Human 4.2 pEC50 = 4.2 Functional
UnclassifiedUnclassified
Guide to Pharmacology 586 7 6 13 1.1 C=C[C@@H]1[C@@H]2CCOC(=O)C2=CO[C@H]1O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)OC(=O)C4=C(C=C(C=C4O)O)C5=CC(=CC=C5)O 26406243
12459 387 0 None -165 3 Human 4.2 pEC50 = 4.2 Functional
UnclassifiedUnclassified
Guide to Pharmacology 586 7 6 13 1.1 C=C[C@@H]1[C@@H]2CCOC(=O)C2=CO[C@H]1O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)OC(=O)C4=C(C=C(C=C4O)O)C5=CC(=CC=C5)O 26406243
5318517 412 0 None 1 3 Human 4.9 pEC50 = 4.9 Functional
UnclassifiedUnclassified
Guide to Pharmacology 350 3 3 5 2.0 OC[C@]1(C)[C@H](O)CC[C@@]2([C@@H]1CCC(=C)[C@H]2C/C=C/1\[C@H](O)COC1=O)C 26406243
9675 412 0 None 1 3 Human 4.9 pEC50 = 4.9 Functional
UnclassifiedUnclassified
Guide to Pharmacology 350 3 3 5 2.0 OC[C@]1(C)[C@H](O)CC[C@@]2([C@@H]1CCC(=C)[C@H]2C/C=C/1\[C@H](O)COC1=O)C 26406243
102129367 588 0 None -3 2 Human 4.9 pEC50 = 4.9 Functional
UnclassifiedUnclassified
Guide to Pharmacology 330 1 1 4 2.6 C[C@@]12CC(=O)C3=C([C@H]1CC[C@]45[C@H]2[C@@H]6C[C@H](C4)[C@@](C5)(O6)CO)CCO3 32437139
12469 588 0 None -3 2 Human 4.9 pEC50 = 4.9 Functional
UnclassifiedUnclassified
Guide to Pharmacology 330 1 1 4 2.6 C[C@@]12CC(=O)C3=C([C@H]1CC[C@]45[C@H]2[C@@H]6C[C@H](C4)[C@@](C5)(O6)CO)CCO3 32437139
12458 226 0 None -25 2 Human 5.0 pEC50 = 5 Functional
UnclassifiedUnclassified
Guide to Pharmacology 496 0 2 6 3.8 C[C@H]1[C@@H]2CC[C@]([C@@H]3[C@H]4[C@H]5C=C([C@@]6([C@H]4C(=C3[C@H]2OC1=O)C)[C@@H]5[C@@](CC[C@@H]7[C@@H]6OC(=O)[C@H]7C)(C)O)C)(C)O 17595105
442138 226 0 None -25 2 Human 5.0 pEC50 = 5 Functional
UnclassifiedUnclassified
Guide to Pharmacology 496 0 2 6 3.8 C[C@H]1[C@@H]2CC[C@]([C@@H]3[C@H]4[C@H]5C=C([C@@]6([C@H]4C(=C3[C@H]2OC1=O)C)[C@@H]5[C@@](CC[C@@H]7[C@@H]6OC(=O)[C@H]7C)(C)O)C)(C)O 17595105
CHEMBL4647301 226 0 None -25 2 Human 5.0 pEC50 = 5 Functional
UnclassifiedUnclassified
Guide to Pharmacology 496 0 2 6 3.8 C[C@H]1[C@@H]2CC[C@]([C@@H]3[C@H]4[C@H]5C=C([C@@]6([C@H]4C(=C3[C@H]2OC1=O)C)[C@@H]5[C@@](CC[C@@H]7[C@@H]6OC(=O)[C@H]7C)(C)O)C)(C)O 17595105
12468 1834 0 None 1 2 Human 5.3 pEC50 = 5.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 262 0 1 4 1.2 C[C@H]1[C@H]2[C@@H](CC1=O)C(=C)C[C@@H]([C@@H]3[C@@H]2OC(=O)C3=C)O 26406243
442256 1834 0 None 1 2 Human 5.3 pEC50 = 5.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 262 0 1 4 1.2 C[C@H]1[C@H]2[C@@H](CC1=O)C(=C)C[C@@H]([C@@H]3[C@@H]2OC(=O)C3=C)O 26406243
CHEMBL271958 1834 0 None 1 2 Human 5.3 pEC50 = 5.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 262 0 1 4 1.2 C[C@H]1[C@H]2[C@@H](CC1=O)C(=C)C[C@@H]([C@@H]3[C@@H]2OC(=O)C3=C)O 26406243
2360 3637 41 None 19 2 Human 6.4 pEC50 = 6.4 Functional
UnclassifiedUnclassified
Guide to Pharmacology 334 0 0 3 2.1 O=C1C[C@@H]2OCC=C3[C@H]4[C@@H]2[C@@H]2N1c1ccccc1[C@]12CCN([C@H]1C4)C3 17595105
2484 3637 41 None 19 2 Human 6.4 pEC50 = 6.4 Functional
UnclassifiedUnclassified
Guide to Pharmacology 334 0 0 3 2.1 O=C1C[C@@H]2OCC=C3[C@H]4[C@@H]2[C@@H]2N1c1ccccc1[C@]12CCN([C@H]1C4)C3 17595105
347 3637 41 None 19 2 Human 6.4 pEC50 = 6.4 Functional
UnclassifiedUnclassified
Guide to Pharmacology 334 0 0 3 2.1 O=C1C[C@@H]2OCC=C3[C@H]4[C@@H]2[C@@H]2N1c1ccccc1[C@]12CCN([C@H]1C4)C3 17595105
441071 3637 41 None 19 2 Human 6.4 pEC50 = 6.4 Functional
UnclassifiedUnclassified
Guide to Pharmacology 334 0 0 3 2.1 O=C1C[C@@H]2OCC=C3[C@H]4[C@@H]2[C@@H]2N1c1ccccc1[C@]12CCN([C@H]1C4)C3 17595105
CHEMBL227934 3637 41 None 19 2 Human 6.4 pEC50 = 6.4 Functional
UnclassifiedUnclassified
Guide to Pharmacology 334 0 0 3 2.1 O=C1C[C@@H]2OCC=C3[C@H]4[C@@H]2[C@@H]2N1c1ccccc1[C@]12CCN([C@H]1C4)C3 17595105
DB15954 3637 41 None 19 2 Human 6.4 pEC50 = 6.4 Functional
UnclassifiedUnclassified
Guide to Pharmacology 334 0 0 3 2.1 O=C1C[C@@H]2OCC=C3[C@H]4[C@@H]2[C@@H]2N1c1ccccc1[C@]12CCN([C@H]1C4)C3 17595105
12499 2238 0 None 1 2 Human 6.5 pEC50 = 6.5 Functional
UnclassifiedUnclassified
Guide to Pharmacology 410 4 2 7 1.8 CC1=C2[C@@H]([C@@H]3[C@@H]([C@H](C1)OC(=O)CC4=CC=C(C=C4)O)C(=C)C(=O)O3)C(=CC2=O)CO 36601079
174880 2238 0 None 1 2 Human 6.5 pEC50 = 6.5 Functional
UnclassifiedUnclassified
Guide to Pharmacology 410 4 2 7 1.8 CC1=C2[C@@H]([C@@H]3[C@@H]([C@H](C1)OC(=O)CC4=CC=C(C=C4)O)C(=C)C(=O)O3)C(=CC2=O)CO 36601079
12472 97 0 None - 1 Human 5.3 pIC50 = 5.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 250 0 1 3 2.6 C[C@@H]1[C@@H]2CC/C(=C\C[C@@H](/C(=C\[C@H]2OC1=O)/C)O)/C 21994393
90471461 97 0 None - 1 Human 5.3 pIC50 = 5.3 Functional
UnclassifiedUnclassified
Guide to Pharmacology 250 0 1 3 2.6 C[C@@H]1[C@@H]2CC/C(=C\C[C@@H](/C(=C\[C@H]2OC1=O)/C)O)/C 21994393


Get vendors


Ligands Receptor Assay information Chemical information
Sel. page Common
name		 GPCRdb ID #Vendors Reference
ligand		 Fold selectivity
(Affinity)		 # tested GPCRs
(Affinity)		 Species p-value
(-log)		 Type Activity
Relation		 Activity
Value		 Assay Type Assay Description Source Mol
weight		 Rot
Bonds		 H don H acc LogP Smiles DOI